Skip to Content
  1. Authors
  2. Damien Conover

Damien Conover

Damien Conover, CFA, is director of healthcare equity research and equity strategy for Morningstar.


The wide-moat pharma firm’s third-quarter results were slightly ahead of our expectations, and we think the market continues to underappreciate the value of the company’s pipeline, writes Morningstar’s Damien Conover.

Strong drug sales helped wide-moat J&J report a steady quarter, but increasing competitive threats to leading drugs and a relatively weak late-stage pipeline will be headwinds in the future.

The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover.

Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover.